Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Senkus, S. Kyriakides, F. Penault-Llorca, P. Poortmans, Alistair Thompson, S. Zackrisson, F. Cardoso (2019)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 24 Suppl 6
Anna-Karin Falck, M. Fernö, P. Bendahl, L. Rydén (2013)
Gallen molecular subtypes in primary breast cancer and matched lymph node metastases-aspects on distribution and prognosis for patients with luminal A tumours : results from a prospective randomised trial
M. Dowsett, T. Nielsen, R. A’Hern, J. Bartlett, R. Coombes, J. Cuzick, M. Ellis, N. Henry, J. Hugh, T. Lively, L. McShane, S. Paik, F. Penault-Llorca, Ljudmila Prudkin, M. Regan, J. Salter, C. Sotiriou, I. Smith, G. Viale, J. Zujewski, D. Hayes (2011)
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.Journal of the National Cancer Institute, 103 22
Monica Boros, C. Podoleanu, R. Georgescu, C. Moldovan, C. Molnar, S. Stolnicu (2015)
Multifocal/multicentric breast carcinomas showing intertumoural heterogeneity: a comparison of histological tumour type and Nottingham histological grade of primary tumour and lymph node metastasis.Polish journal of pathology : official journal of the Polish Society of Pathologists, 66 2
Sarah Aitken, J. Thomas, S. Langdon, D. Harrison, D. Faratian (2010)
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.Annals of oncology : official journal of the European Society for Medical Oncology, 21 6
L. Lindström, E. Karlsson, U. Wilking, U. Johansson, J. Hartman, E. Lidbrink, T. Hatschek, L. Skoog, J. Bergh (2012)
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
V. Fulga, Lucian Rudico, Amalia Balica, A. Cîmpean, L. Saptefrati, M. Raica (2015)
Invasive ductal carcinoma of no special type and its corresponding lymph node metastasis: do they have the same immunophenotypic profile?Polish journal of pathology : official journal of the Polish Society of Pathologists, 66 1
L. Nedergaard, T. Haerslev, G. Jacobsen (1995)
Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodiesAPMIS, 103
Anna-Karin Falck, M. Fernö, P. Bendahl, L. Rydén (2013)
St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trialBMC Cancer, 13
Monica Boros, C. Marian, C. Moldovan, S. Stolnicu (2012)
Morphological heterogeneity of the simultaneous ipsilateral invasive tumor foci in breast carcinoma: a retrospective study of 418 cases of carcinomas.Pathology, research and practice, 208 10
M. Hammond (2011)
ASCO-CAP Guidelines for Breast Predictive Factor Testing: An UpdateApplied Immunohistochemistry & Molecular Morphology, 19
J. Jensen, A. Knoop, M. Ewertz, A. Laenkholm (2012)
ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancerBreast Cancer Research and Treatment, 132
M. Hammond, Daniel Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, Neil Goldstein, M. Hayes, David Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, Jared Schwartz, F. Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. Williams, J. Wittliff, Antonio Wolff (2010)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.Archives of pathology & laboratory medicine, 134 6
C. Ng, A. Schultheis, F. Bidard, B. Weigelt, J. Reis-Filho (2015)
Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.Journal of the National Cancer Institute, 107 5
(2012)
HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer
(2015)
Tailoring therapiesimproving the management of early breast carcinoma
A. Ieni, V. Barresi, R. Caltabiano, A. Cascone, R. Sordo, D. Cabibi, P. Zeppa, S. Lanzafame, A. Sidoni, V. Franco, G. Tuccari (2014)
Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigationOncoTargets and therapy, 7
(2015)
progesterone receptor negativity of the primary tumor is not shown in this picture. ison of histological tumour type and Nottingham histological grade of primary tumour and lymph node metastasis
J. Boyages, U. Jayasinghe, N. Coombs (2010)
Multifocal breast cancer and survival: each focus does matter particularly for larger tumours.European journal of cancer, 46 11
B. Ataseven, D. Gologan, Angela Gunesch, V. Kehl, B. Hoegel, Michael Beer, W. Eiermann (2012)
HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification CharacteristicsBreast Care, 7
T. Tot, M. Gere, G. Pekar, M. Tarján, S. Hofmeyer, D. Hellberg,, D. Lindquist, T. Chen, A. Yen, S. Chiu, L. Tabár (2011)
Breast cancer multifocality, disease extent, and survival.Human pathology, 42 11
Antonio Wolff, M. Hammond, Jared Schwartz, K. Hagerty, D. Allred, Richard Cote, M. Dowsett, P. Fitzgibbons, Wedad Hanna, A. Langer, L. McShane, S. Paik, M. Pegram, Edith Perez, Michael Press, A. Rhodes, C. Sturgeon, S. Taube, R. Tubbs, Gail Vance, Marc Vijver, Thomas Wheeler, Daniel Hayes (2006)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.Archives of pathology & laboratory medicine, 131 1
A. Coates, E. Winer, A. Goldhirsch, R. Gelber, M. Gnant, M. Piccart-Gebhart, B. Thürlimann, H. Senn (2015)
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Annals of Oncology, 26
Zi-xiang Yao, Lin-jie Lu, Rui-jue Wang, Liang-bin Jin, Sheng-chun Liu, Hong-Yuan Li, G. Ren, Kai-nan Wu, De-lin Wang, Ling-quan Kong (2013)
Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasisMedical Oncology, 31
A. Goldhirsch, W. Wood, A. Coates, R. Gelber, B. Thürlimann, H. Senn, Panel Members (2011)
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 22
Background:We aimed to demonstrate that in breast carcinomas the tumor profile is not stable during the metastatic process, with impact on therapeutic decisions.Materials and Methods:We analyzed the estrogen receptor (ER), progesterone receptor (PR), and HER2 status and Ki67 index in 41 primary unifocal (PU) and 37 primary multiple (PM) breast carcinomas with identical immunohistochemical profiles among multiple tumor foci and the matched axillary lymph node metastases. We defined as concordant cases in which the primary tumor (PU or PM) and lymph node metastases displayed identical positivity or negativity for ER, PR, HER2, Ki67 and as discordant cases in which there was a mismatch in at least 1 biological parameter among PU and PM tumor and lymph node metastases. Moreover, we defined as concordant cases in which the molecular profile (based on the immunohistochemical evaluation of ER, PR, HER2, and Ki67) was concordant among PU and PM tumors and lymph node metastases and mismatch cases as those in which the molecular profile of the primary tumor differs from one of the lymph node metastases in at least 1 lymph node.Results:The positivity for the biological markers is not stable during the metastatic process. In this study the total rate of discordant cases was 92.7% in PU tumors and 75.7% in PM homogenous tumors (P=0.058, odds ratio=0.245, 95% confidence interval, 0.06-0.991). The total rate of shifted cases was 64.9% in PM tumors and 82.9% in PU tumors. The highest rate of shifting was encountered from Luminal B-like to Luminal A-like. In 11 out of 37 (29.7%) PM and in 17 out of 41 (41.5%) PU cases the subtype shifted to a poorer one with respect to prognosis.Conclusions:The patients in whom the primary tumor is hormone receptor and/or HER2 negative but is positive for these markers in the axillary lymph nodes could become eligible for hormonal treatment and/or trastuzumab treatment, which may significantly improve the patient’s outcome.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Sep 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.